India’s Pharmaceutical Industry Growth and Global Impact

India’s pharmaceutical sector continues to expand rapidly in 2026. It plays a vital role in public health and economic development. The industry is a global leader in generic medicines and vaccines. Recent trade agreements with the EU, UK, and New Zealand are boosting exports and investments. Government schemes support manufacturing, innovation, and affordability. This knowledge base summarises the key developments and facts about India’s pharmaceutical industry.

India’s Position in Global Pharmaceuticals

India ranks 3rd globally by volume and 11th by value in pharmaceuticals. It supplies 20% of global generic medicines and 60,000 generic brands. The domestic market is worth USD 60 billion, expected to reach USD 130 billion by 2030. India leads in vaccine supply for diseases like DPT, BCG, and measles. It hosts the highest number of USFDA-approved plants outside the USA. The pharmaceutical export reached USD 30.5 billion in 2024-25, serving 191 countries. Half of exports go to regulated markets like the US and Europe.

Government Initiatives and Production Linked Incentives

PLI schemes strengthen domestic manufacturing of pharmaceuticals, bulk drugs, and medical devices. They reduce import dependence and boost exports. Investments under these schemes exceed targets, generating thousands of jobs. Bulk Drug Parks and Medical Device Parks provide common infrastructure in various states. The PMBJP scheme improves access to affordable generic medicines through over 18,600 Jan Aushadhi Kendras nationwide. Research promotion through PRIP supports innovation and industry-academia collaboration.

Trade Agreements and Foreign Investment

India’s Free Trade Agreements with the EU, UK, and New Zealand enhance market access. These agreements reduce tariffs on medicines and medical devices, increasing competitiveness. India’s pharmaceutical exports diversify into emerging markets like Nigeria, Mexico, and Brazil. Foreign Direct Investment in the sector reached over Rs. 13,000 crore in 2025-26, reflecting strong investor confidence.

Regulatory Framework and Quality Assurance

The Central Drugs Standard Control Organisation (CDSCO) regulates drug approvals and safety. The National Pharmaceutical Pricing Authority (NPPA) controls drug prices to ensure affordability. The Indian Pharmacopoeia Commission (IPC) sets quality standards for medicines. These institutions maintain high safety and quality standards, reinforcing global trust in Indian pharmaceuticals.

Topics for Prelims:

Indian Pharmaceutical Industry

1. Ranks 3rd globally by volume and 11th by value.
2. Largest supplier of generic medicines (20% global supply).
3. Hosts most USFDA-approved plants outside the USA.
4. Domestic market valued at USD 60 billion (2026).
5. Exports medicines to 191 countries.

Production Linked Incentive (PLI) Schemes

1. Supports pharma, bulk drugs, and medical device manufacturing.
2. Generated nearly 1 lakh jobs by 2025.
3. Reduced import dependence on critical APIs and intermediates.
4. Investment mobilised exceeds Rs. 40,000 crore in pharma.
5. Includes development of Bulk Drug and Medical Device Parks.

Trade Agreements and Regulatory Bodies

1. India-EU FTA enhances pharma market access.
2. India-UK CETA offers zero-duty access on 56 pharma tariff lines.
3. India-New Zealand FTA reduces duties on pharma products.
4. CDSCO regulates drug safety and clinical trials.
5. NPPA manages drug pricing under DPCO 2013.

Questions for Mains:

1. Critically analyse the impact of India’s Production Linked Incentive schemes on reducing import dependence in the pharmaceutical sector. With suitable examples, estimate their role in enhancing India’s global competitiveness. [GS-III-Economic Development]
2. Point out the significance of India’s Free Trade Agreements with the European Union and the United Kingdom in expanding pharmaceutical exports and foreign investment. How do these agreements align with India’s broader economic diplomacy goals? [GS-II-International Relations]
3. Underline the role of regulatory bodies like the Central Drugs Standard Control Organisation and the National Pharmaceutical Pricing Authority in ensuring drug safety and affordability in India. Critically analyse the challenges faced by these institutions. [GS-II-Constitution of India & Polity]
4. With suitable examples, estimate the contribution of India’s pharmaceutical sector to public health outcomes globally. How does this sector influence socio-economic development domestically and internationally? [GS-I-Indian Society]

Answer Hints:

1. Critically analyse the impact of India’s Production Linked Incentive schemes on reducing import dependence in the pharmaceutical sector. With suitable examples, estimate their role in enhancing India’s global competitiveness. [GS-III-Economic Development]

1. PLI schemes incentivize domestic manufacturing of APIs, KSMs, DIs, and complex pharma products, reducing import reliance (e.g., avoidance of imports worth Rs. 3,591 crore).
2. They have mobilized investments exceeding targets (Rs. 40,890 crore in pharma), boosting production capacity and supply chain resilience.
3. Generation of nearly 1 lakh direct and indirect jobs enhances skilled workforce and industrial growth.
4. Export growth supported by PLI schemes (Rs. 2,03,730 crore pharma exports under PLI) strengthens India’s position in global markets.
5. Development of Bulk Drug Parks and Medical Device Parks under PLI reduces cost and dependency on imports through shared infrastructure.
6. Overall, PLI schemes promote self-reliance (Atmanirbhar Bharat), improve quality standards, and enhance India’s competitiveness as a global pharmaceutical hub.

2. Point out the significance of India’s Free Trade Agreements with the European Union and the United Kingdom in expanding pharmaceutical exports and foreign investment. How do these agreements align with India’s broader economic diplomacy goals? [GS-II-International Relations]

1. India-EU FTA offers enhanced market access to a USD 572.3 billion market, boosting pharma and medical devices exports through tariff liberalization.
2. India-UK CETA provides zero-duty access on 56 pharmaceutical tariff lines and duty-free access on several medical devices, improving competitiveness in a key export market.
3. These agreements attract foreign investment by improving regulatory alignment and market predictability.
4. Trade deals diversify export destinations, reducing dependence on traditional markets and mitigating tariff risks.
5. Aligns with India’s economic diplomacy to deepen global trade linkages, promote ‘Make in India,’ and integrate India into global healthcare value chains.
6. Supports India’s ambition to be a global pharma manufacturing hub and a reliable supplier of affordable medicines worldwide.

3. Underline the role of regulatory bodies like the Central Drugs Standard Control Organisation and the National Pharmaceutical Pricing Authority in ensuring drug safety and affordability in India. Critically analyse the challenges faced by these institutions. [GS-II-Constitution of India & Polity]

1. CDSCO regulates drug approvals, clinical trials, manufacturing licenses, and pharmacovigilance, ensuring safety and efficacy of medicines.
2. NPPA controls drug prices under DPCO 2013 to maintain affordability and monitor compliance, preventing exploitative pricing.
3. Both institutions uphold public health by enforcing standards and ensuring availability of essential drugs.
4. Challenges include regulatory delays, capacity constraints, balancing innovation with price control, and ensuring compliance across a vast and fragmented pharma sector.
5. Need for continuous updating of regulations to keep pace with evolving technologies and global standards.
6. Coordination between central and state bodies, and managing conflicts between industry interests and public health priorities remain critical issues.

4. With suitable examples, estimate the contribution of India’s pharmaceutical sector to public health outcomes globally. How does this sector influence socio-economic development domestically and internationally? [GS-I-Indian Society]

1. India supplies around 20% of global generic medicines and 60% of vaccines to UNICEF, including DPT, BCG, and measles vaccines, improving global immunization coverage.
2. Affordable medicines and vaccines from India improve access to healthcare in low- and middle-income countries, reducing disease burden and mortality.
3. Domestically, the sector generates employment for nearly 1 lakh people, supporting livelihoods and economic growth.
4. Pharma exports worth USD 30.5 billion integrate India into global health supply chains, strengthening economic resilience.
5. Government schemes like PMBJP reduce out-of-pocket expenditure for Indian citizens, enhancing equitable access to essential medicines.
6. The sector’s growth encourages technological advancement, research innovation (e.g., biopharma initiatives), and infrastructure development, contributing to overall socio-economic progress.